Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-07

Clinical Trial Update: Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating hematin to prevent post-ERCP acute pancreatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Hemin (hemin)

Snippet

Sponsor: Erasme University Hospital | Conditions: Post-ERCP Acute Pancreatitis | Phase 2 | Status: COMPLETED